Pfizer Inc. Release: Court In The Netherlands Upholds Basic Lipitor Patent, Prevents Launch Of Ranbaxy Laboratories Product Before November 2011

NEW YORK, Sept. 13 /PRNewswire-FirstCall/ -- Pfizer Inc said today that the District Court of The Hague in the Netherlands has ruled that the basic patent covering atorvastatin -- the active ingredient in Lipitor -- would be infringed by a competitor product from generics manufacturer Ranbaxy. The decision, which is subject to appeal, prevents Ranbaxy from launching its drug before Lipitor’s basic patent (EP 247,633) expires in November 2011.

MORE ON THIS TOPIC